Anti-IL-23 monoclonal biologic antibodies Archives

U.S. FDA Approves Second Indication for Skyrizi to Treat Adults with Active Psoriatic Arthritis

AbbVie, Active Psoriatic Arthritis (PsA), Adults, Anti-IL-23 monoclonal biologic antibodies, Approvals, Blockbusters, Clinical Trial Endpoints, COVID-19 Therapeutics, Inflammatory Diseases, Joints, New Indications, Plaque Psoriasis, Primary Endpoints, Psoriasis

The U.S. Food and Drug Administration approved AbbVie’s Skyrizi (risankizumab-rzaa) for the treatment of adults with active psoriatic arthritis (PsA), a systemic inflammatory disease that affects the skin and joints and impacts 30 percent of patients with psoriasis.

AstraZeneca Reports Success in Stroke and Gastric Cancer Trials

Anti-IL-23 monoclonal biologic antibodies, Antibody-Drug Conjugates (ADCs), Blockbusters, Business, Clinical Trials, Deals, Gastric Cancer, Monoclonal Antibodies, Product Pipeline, R&D, Strokes

AstraZeneca announced that the company’s Brilinta (ticagrelor) hit the primary endpoint in the Phase III THALES trial in stroke.

J&J’s Tremfya Shows Extended Success in Treating Plaque Psoriasis

Anti-IL-23 monoclonal biologic antibodies, Biologics, Blockbusters, Clinical Trials, Hidradenitis suppurativa, Immune-Mediated Diseases, Monoclonal Antibodies, Plaque Psoriasis, Psoriasis, R&D, Ulcerative Colitis

J&J’s Janssen Pharmaceutical released new long-term data from the open-label period of the Phase III VOYAGE 1 study.